Patent · US Active

T cell receptors and peptides derived by mutations for the treatment of cancer

US11614449B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

TECHNISCHE UNIVERSITÄT MÜNCHEN · DE

Inventors

Markus Gerhard · Munich, DE
Dirk Busch · Munich, DE
Georg DOESSINGER · Munich, DE
Antonius Nicolaas Maria Schumacher · Haarlem, NL
Carsten Linnemann · Amsterdam, NL

Key dates

Filing date	Mar 31, 2016
Grant date	Mar 28, 2023
Priority date	—
Expiry date	Apr 17, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70539
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.